Results 1 to 10 of about 192,096 (187)

ASOG: AntiSense Oligonucleotide Generator [PDF]

open access: yesComputational and Structural Biotechnology Journal
Antisense oligonucleotides (ASOs) are used in both fundamental research and clinical applications to modulate gene expression by targeting the RNA transcript of specific genes.
Jonah Kimi   +6 more
doaj   +2 more sources

Pharmacokinetics of antisense oligonucleotide drugs [PDF]

open access: yesФармакокинетика и Фармакодинамика, 2013
This review covers the pharmacokinetic characteristics of the various antisense oligonucleotide drugs. A comparison of the pharmacokinetics of drugs first and second generation.
M. R. Khaitov, V. V. Smirnov
doaj   +1 more source

Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics [PDF]

open access: yes, 2008
Antisense oligonucleotides (As-ODNs) are single stranded, synthetically prepared strands of deoxynucleotide sequences, usually 18–21 nucleotides in length, complementary to the mRNA sequence of the target gene.
Mansoor, Moizza, Melendez, Alirio J.
core   +8 more sources

Antisense oligonucleotide targeting nicotinamide N-methyltransferase exhibits antitumor effects [PDF]

open access: yesMolecular Therapy: Nucleic Acids
Nicotinamide N-methyltransferase (NNMT) is one of the methyltransferase family genes. It consumes S-adenosyl-l-methionine (SAM), which is required for DNA methylation and histone methylation for epigenetic regulation, to produce 1-methylnicotinamide from
Tomoaki Hara   +13 more
doaj   +2 more sources

Antisense oligonucleotides [PDF]

open access: yesNeurology Genetics, 2019
There are few disease-modifying therapeutics for neurodegenerative diseases, but successes on the development of antisense oligonucleotide (ASO) therapeutics for spinal muscular atrophy and Duchenne muscular dystrophy predict a robust future for ASOs in medicine.
Scoles, Daniel R.   +2 more
openaire   +3 more sources

Antisense oligonucleotides for neurodegeneration [PDF]

open access: yesScience, 2020
Promising clinical results for Huntington's disease give hope for other ...
Leavitt, BR, Tabrizi, SJ
openaire   +3 more sources

History of Research on Antisense Oligonucleotide Analogs

open access: yesSubstantia, 2021
In the search for novel therapeutics, antisense oligonucleotide (ASO) analogs have been a major focus of research for over 40 years.  They use the antisense strategy, namely they have a nucleic acid base sequence that is complementary to a portion of a ...
Jack S. Cohen
doaj   +1 more source

An Investigation into the Potential of Targeting Escherichia coli rne mRNA with Locked Nucleic Acid (LNA) Gapmers as an Antibacterial Strategy

open access: yesMolecules, 2021
The increase in antibacterial resistance is a serious challenge for both the health and defence sectors and there is a need for both novel antibacterial targets and antibacterial strategies.
Layla R. Goddard   +9 more
doaj   +1 more source

A perspective on oligonucleotide therapy: Approaches to patient customization

open access: yesFrontiers in Pharmacology, 2022
It is estimated that the human genome encodes 15% of proteins that are considered to be disease-modifying. Only 2% of these proteins possess a druggable site that the approved clinical candidates target. Due to this disparity, there is an immense need to
Shikha Thakur   +3 more
doaj   +1 more source

Antisense oligonucleotides or oligonucleotide analogues [PDF]

open access: yes, 2013
The present invention relates to antisense oligonucleotides or oligonucleotide analogues adapted to target pre-mRNA which encodes GNB3s and prevent aberrant splicing events.
Lester, Douglas H.
core   +6 more sources

Home - About - Disclaimer - Privacy